Icariin improves erectile function in spontaneously hypertensive rats by downregulating GRK2 in penile cavernous tissue
The Journal of Sexual Medicine · 2025
DOI: 10.1093/jsxmed/qdaf014 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Sexual Medicine, 2025. Verfasst von Yanke Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China. Hauptthemen laut MEDLINE: Penis, Flavonoids, Erectile Dysfunction, G-Protein-Coupled Receptor Kinase 2. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Sichuan Science and Technology Plan, Science and Technology Department in Sichuan Province.
Abstract (Originalsprache)
Background
Hypertension is an independent risk factor for erectile dysfunction (ED). Icariin can improve erectile function of spontaneous hypertensive rats (SHRs). GRK2 is closely related to the phosphorylation of eNOS and endothelial function.
Aim
To explore whether icariin can improve erectile function in SHRs by regulating the expression of GRK2 in penile cavernous tissue.
Methods
Eight-week-old WKY and SHR rats were randomly divided into four groups (n = 6 per group) as follows: WKY, WKY + icariin, SHR and SHR + icariin. The WKY + icariin and SHR + icariin groups were treated with 10 mg/kg/day icariin. After 4 weeks, the ICPmax/mean arterial pressure (MAP), serum testosterone, the levels of GRK2, p-AKT/AKT, p-eNOS/eNOS, and caspase-3; the protein interaction between GRK2 and AKT; the levels of nitric oxide (NO), superoxide dismutase (SOD), and malondialdehyde (MDA); and the level of apoptosis in rat penile cavernous tissue were measured. Outcome The expression of GRK2 in penile cavernous tissue of SHR was significantly higher than that in WKY rats, resulting in the inhibition of the AKT/eNOS/NO pathway, increased levels of oxidative stress and apoptosis, and the impairment of erectile function.
Results
The ICPmax/MAP ratio in the SHR group was significantly lower than those in WKY and SHR + icariin groups (P < .01). In the SHR + icariin group, the expression levels of GRK2 and caspase-3, the interaction between GRK2 and AKT, the level of MDA and the rate of apoptosis in the penile cavernous tissue were significantly lower, and the levels of p-AKT and p-eNOS, the p-AKT/AKT and p-eNOS/eNOS ratios, and NO and SOD were significantly greater than those in the SHR group (P < .01). Clinical Implications Icariin may improve the erectile function of hypertension by downregulating GRK2 expression in penile cavernous tissue. Strengths and Limitations The specific mechanism via which icariin downregulates GRK2 needs to be further elucidated.
Conclusion
Icariin downregulates the expression of GRK2 in the penile cavernous tissue of SHRs, upregulates the AKT/eNOS/NO pathway, decreases oxidative stress and apoptosis, and ultimately improves erectile function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China.
- Department of Thyroid Surgery, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China.
Förderung
- Sichuan Science and Technology Plan
- Science and Technology Department in Sichuan Province
Zitieren
APA
Li, Y., Jiang, J., & Jiang, R. (2025). Icariin improves erectile function in spontaneously hypertensive rats by downregulating GRK2 in penile cavernous tissue. The Journal of Sexual Medicine. https://doi.org/10.1093/jsxmed/qdaf014
Vancouver
Li Y, Jiang J, Jiang R. Icariin improves erectile function in spontaneously hypertensive rats by downregulating GRK2 in penile cavernous tissue. The Journal of Sexual Medicine. 2025. doi:10.1093/jsxmed/qdaf014
BibTeX
@article{Li2025,
author = {Li, Yanke and Jiang, Jun and Jiang, Rui},
title = {Icariin improves erectile function in spontaneously hypertensive rats by downregulating GRK2 in penile cavernous tissue},
journal = {The Journal of Sexual Medicine},
year = {2025},
doi = {10.1093/jsxmed/qdaf014}
}
EUVIMED